You are here
Articles on Gastrointestinal Cancer
A selection of peer-reviewed articles on Gastrointestinal Cancer. All content available on the Advances in Gastrointestinal Cancer Resource Center, including original and review articles, interviews, guidelines and congress highlights, is independently selected by the members of the Editorial Board.
Patients with Peritoneal Carcinomatosis from Gastric Cancer Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Is Cure a Possibility?
Chia CS, You B, Decullier E, Vaudoyer D, Lorimier G, Abboud K, et al.Ann Surg Oncol. 2016 Jun;23(6):1971-9.
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
Muro K, Chung HC, Shankaran V, Geva R, Catenacci D, Gupta S, et al.Lancet Oncol. 2016 May 3. [Epub ahead of print]
Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial
Tebbutt NC, Price TJ, Ferraro DA, Wong N, Veillard AS, Hall M, et alBr J Cancer. 2016 Mar 1;114(5):505-9
Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study
Meulendijks D, de Groot JW, Los M, Boers JE, Beerepoot LV, Polee MB, et alCancer. 2016 May 1;122(9):1434-43.
A phase II prospective study of the trastuzumab combined with 5-weekly S-1 and CDDP therapy for HER2-positive advanced gastric cancer
Kataoka H, Mori Y, Shimura T, Nishie H, Natsume M, Mochizuki H, et al.Cancer Chemother Pharmacol. 2016 Mar 22. [Epub ahead of print]
Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer
Kim ST, Lee J, Lee SJ, Park SH, Jung SH, Park YS, Lim HY, Kang WK, Park JOOncotarget. 2016 Mar 18. [Epub ahead of print]
Evaluation of Angiopoietin-2 as a biomarker in gastric cancer: results from the randomised phase III AVAGAST trial
Hacker UT, Escalona-Espinosa L, Consalvo N, Goede V, Schiffmann L, Scherer SJ, et alBr J Cancer. 2016 Apr 12;114(8):855-62
Feasibility of weekly intraperitoneal versus intravenous paclitaxel therapy delivered from the day of radical surgery for gastric cancer: a preliminary safety analysis of the INPACT study, a randomized controlled trial
Kodera Y, Takahashi N, Yoshikawa T, Takiguchi N, Fujitani K, Ito Y, et al.Gastric Cancer. 2016 Feb 15. [Epub ahead of print]